Murine models for HIV vaccination and challenge

References

• Alter HJ, Eichberg JW, Masur H et al. Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science226(4674), 549–552 (1984).
   PubMedGoogle Scholar
• Rutjens E, Balla-Jhagjhoorsingh S, Verschoor E, Bogers W, Koopman G, Heeney J. Lentivirus infections and mechanisms of disease resistance in chimpanzees. Front Biosci.8, d1134–d1145 (2003).
   Web of Science ®Google Scholar
• Gardner MB. SIV infection of macaques: a model for AIDS vaccine development. Dev. Biol. Stand.72, 259–266 (1990).
   Google Scholar
• Putkonen P, Bjorling E, Akerblom L et al. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. J. Acquir. Immune Defic. Syndr.7(6), 551–559 (1994).
   Google Scholar
• Putkonen P, Thorstensson R, Ghavamzadeh L et al. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature352(6334), 436–438 (1991).
   PubMed Web of Science ®Google Scholar
• Li J, Lord CI, Haseltine W, Letvin NL, Sodroski J. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J. Acquir. Immune Defic. Syndr.5(7), 639–646 (1992).
   PubMed Web of Science ®Google Scholar
• Joag SV, Li Z, Foresman L et al. Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J. Virol.70(5), 3189–3197 (1996).
   PubMed Web of Science ®Google Scholar
• Etemad-Moghadam B, Rhone D, Steenbeke T et al. Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J. Virol.75(12), 5646–5655 (2001).
   Google Scholar
• Reimann KA, Li JT, Veazey R et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol.70(10), 6922–6928 (1996).
   PubMed Web of Science ®Google Scholar
• Warren JT, Levinson MA. AIDS preclinical vaccine development: biennial survey of HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates. J. Med. Primatol.28(4–5), 249–273 (1999).
   PubMed Web of Science ®Google Scholar
• Benson J, Chougnet C, Robert-Guroff M et al. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J. Virol.72(5), 4170–4182 (1998).
   PubMedGoogle Scholar
• Desrosiers RC. Non-human primate models for AIDS vaccines. AIDS9(Suppl. A), S137–S141 (1995).
   Google Scholar
• Podell M, March PA, Buck WR, Mathes LE. The feline model of neuroAIDS: understanding the progression towards AIDS dementia. J. Psychopharmacol.14(3), 205–213 (2000).
   Google Scholar
• Dunham SP. Lessons from the cat: development of vaccines against lentiviruses. Vet Immunol. Immunopathol.112(1–2), 67–77 (2006).
   Google Scholar
• Goffinet C, Allespach I, Keppler OT. HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. Proc. Natl Acad. Sci. USA104(3), 1015–1020 (2007).
   Web of Science ®Google Scholar
• Leonard JM, Abramczuk JW, Pezen DS et al. Development of disease and virus recovery in transgenic mice containing HIV proviral DNA. Science242(4886), 1665–1670 (1988).
   PubMed Web of Science ®Google Scholar
• van Maanen M, Sutton RE. Rodent models for HIV-1 infection and disease. Curr. HIV Res.1(1), 121–130 (2003).
   PubMed Web of Science ®Google Scholar
• Browning J, Horner JW, Pettoello-Mantovani M et al. Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc. Natl Acad. Sci. USA94(26), 14637–14641 (1997).
   PubMed Web of Science ®Google Scholar
• Mariani R, Rutter G, Harris ME, Hope TJ, Krausslich HG, Landau NR. A block to human immunodeficiency virus type 1 assembly in murine cells. J. Virol.74(8), 3859–3870 (2000).
   PubMed Web of Science ®Google Scholar
• Liang C, Wainberg MA. The role of Tat in HIV-1 replication: an activator and/or a suppressor? AIDS Rev.4(1), 41–49 (2002).
   PubMedGoogle Scholar
• Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J.17(23), 7056–7065 (1998).
   PubMed Web of Science ®Google Scholar
• Zheng YH, Yu HF, Peterlin BM. Human p32 protein relieves a post-transcriptional block to HIV replication in murine cells. Nat. Cell Biol.5(7), 611–618 (2003).
   PubMed Web of Science ®Google Scholar
• Schröfelbauer B, Chen D, Landau NR. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl Acad. Sci. USA101(11), 3927–3932 (2004).
   PubMed Web of Science ®Google Scholar
• Sorin M, Kalpana GV. Dynamics of virus–host interplay in HIV-1 replication. Curr. HIV Res.4(2), 117–130 (2006).
   PubMed Web of Science ®Google Scholar
• Goff SP. Retrovirus restriction factors. Mol. Cell16(6), 849 (2004).
   PubMed Web of Science ®Google Scholar
• Goff SP. Genetic control of retrovirus susceptibility in mammalian cells. Annu. Rev. Genet.38, 61–85 (2004).
   PubMed Web of Science ®Google Scholar
• Schutten M, Tenner-Racz K, Racz P, van Bekkum DW, Osterhaus AD. Human antibodies that neutralize primary human immunodeficiency virus type 1 in vitro do not provide protection in an in vivo model. J. Gen. Virol.77 (Pt 8), 1667–1675 (1996).
   Google Scholar
• Marcus H, David M, Canaan A et al. Human/mouse radiation chimera are capable of mounting a human primary humoral response. Blood86(1), 398–406 (1995).
   PubMed Web of Science ®Google Scholar
• Segall H, Lubin I, Marcus H, Canaan A, Reisner Y. Generation of primary antigen-specific human cytotoxic T lymphocytes in human/mouse radiation chimera. Blood88(2), 721–730 (1996).
   PubMed Web of Science ®Google Scholar
• McCune JM. SCID mice as immune system models. Curr. Opin. Immunol.3(2), 224–228 (1991).
   Google Scholar
• McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science241(4873), 1632–1639 (1988).
   PubMed Web of Science ®Google Scholar
• Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature335(6187), 256–259 (1988).
   PubMed Web of Science ®Google Scholar
• Schuler W, Schuler A, Bosma MJ. Defective V-to-J recombination of T cell receptor γ chain genes in scid mice. Eur. J. Immunol.20(3), 545–550 (1990).
   PubMed Web of Science ®Google Scholar
• Boyle MJ, Connors M, Flanigan ME et al. The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapy. J. Immunol.154(12), 6612–6623 (1995).
   Google Scholar
• Tary-Lehmann M, Saxon A, Lehmann PV. The human immune system in hu-PBL-SCID mice. Immunol. Today16(11), 529–533 (1995).
   PubMedGoogle Scholar
• Bonyhadi ML, Kaneshima H. The SCID-hu mouse: an in vivo model for HIV-1 infection in humans. Mol. Med. Today3(6), 246–253 (1997).
   Google Scholar
• McCune JM. Development and applications of the SCID-hu mouse model. Semin. Immunol.8(4), 187–196 (1996).
   PubMedGoogle Scholar
• McCune JM, Peault B, Streeter PR, Rabin L. Preclinical evaluation of human hematolymphoid function in the SCID-hu mouse. Immunol. Rev.124, 45–62 (1991).
   Google Scholar
• McCune JM, Namikawa R, Shih CC, Rabin L, Kaneshima H. Suppression of HIV infection in AZT-treated SCID-hu mice. Science247(4942), 564–566 (1990).
   PubMed Web of Science ®Google Scholar
• Mosier DE, Picchio GR, Gulizia RJ et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol.73(5), 3544–3550 (1999).
   PubMed Web of Science ®Google Scholar
• Borkow G. Mouse models for HIV-1 infection. IUBMB Life57(12), 819–823 (2005).
   PubMed Web of Science ®Google Scholar
• Berges BK, Wheat WH, Palmer BE, Connick E, Akkina R. HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-γc-/- (RAG-hu) mouse model. Retrovirology3, 76 (2006).
   PubMed Web of Science ®Google Scholar
• Delhem N, Hadida F, Gorochov G et al. Primary Th1 cell immunization against HIVgp160 in SCID-hu mice coengrafted with peripheral blood lymphocytes and skin. J. Immunol.161(4), 2060–2069 (1998).
   Google Scholar
• Goldman JP, Blundell MP, Lopes L, Kinnon C, Di Santo JP, Thrasher AJ. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor γ chain. Br. J. Haematol.103(2), 335–342 (1998).
   PubMed Web of Science ®Google Scholar
• Hiramatsu H, Nishikomori R, Heike T et al. Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/γcnull mice model. Blood102(3), 873–880 (2003).
   PubMed Web of Science ®Google Scholar
• Traggiai E, Chicha L, Mazzucchelli L et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science304(5667), 104–107 (2004).
   PubMed Web of Science ®Google Scholar
• An DS, Poon B, Fang RHT et al. Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection. Clin. Vaccine Immunol.14(4), 391–396 (2007).
   PubMed Web of Science ®Google Scholar
• Chicha L, Tussiwand R, Traggiai E et al. Human adaptive immune system Rag2-/-γ(c)-/- mice. Ann. NY Acad. Sci.1044, 236–243 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang L, Kovalev GI, Su L. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood109(7), 2978–2981 (2007).
   PubMed Web of Science ®Google Scholar
• Mazurier F, Fontanellas A, Salesse S et al. A novel immunodeficient mouse model – RAG2 x common cytokine receptor γ chain double mutants – requiring exogenous cytokine administration for human hematopoietic stem cell engraftment. J. Interferon Cytokine Res.19(5), 533–541 (1999).
   PubMed Web of Science ®Google Scholar
• Baenziger S, Tussiwand R, Schlaepfer E et al. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-γ c-/- mice. Proc. Natl Acad. Sci. USA103(43), 15951–15956 (2006).
   PubMed Web of Science ®Google Scholar
• Ayash-Rashkovsky M, Bentwich Z, Arditti F, Friedman S, Reisner Y, Borkow G. A novel small animal model for HIV-1 infection. FASEB J.19(9), 1149–1151 (2005).
   PubMed Web of Science ®Google Scholar
• Ayash-Rashkovsky M, Borkow G, Davis HL, Moss RB, Bartholomew R, Bentwich Z. Enhanced HIV-1 specific immune response by CpG ODN and HIV-1 immunogen-pulsed dendritic cells confers protection in the Trimera murine model of HIV-1 infection. FASEB J.19(9), 1152–1154 (2005).
   Google Scholar
• Lubin I, Faktorowich Y, Lapidot T et al. Engraftment and development of human T and B cells in mice after bone marrow transplantation. Science252(5004), 427–431 (1991).
   PubMed Web of Science ®Google Scholar
• Lubin I, Segall H, Marcus H et al. Engraftment of human peripheral blood lymphocytes in normal strains of mice. Blood83(8), 2368–2381 (1994).
   PubMed Web of Science ®Google Scholar
• Garcia S, Dadaglio G, Gougeon ML. Limits of the human-PBL-SCID mice model: severe restriction of the V β T-cell repertoire of engrafted human T cells. Blood89(1), 329–336 (1997).
   PubMed Web of Science ®Google Scholar
• Saxon A, Macy E, Denis K, Tary-Lehmann M, Witte O, Braun J. Limited B cell repertoire in severe combined immunodeficient mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans. J. Clin. Invest.87(2), 658–665 (1991).
   PubMed Web of Science ®Google Scholar
• Klotman PE, Notkins AL. Transgenic models of human immunodeficiency virus type-1. Curr. Top. Microbiol. Immunol.206, 197–222 (1996).
   PubMedGoogle Scholar
• Brady HJ, Pennington DJ, Dzierzak EA. Transgenic mice as models of human immunodeficiency virus expression and related cellular effects. J. Gen. Virol.75(Pt 10), 2549–2558 (1994).
   PubMed Web of Science ®Google Scholar
• Kopp JB, Rooney JF, Wohlenberg C et al. Cutaneous disorders and viral gene expression in HIV-1 transgenic mice. AIDS Res. Hum. Retroviruses9(3), 267–275 (1993).
   Google Scholar
• Lewis W. Use of the transgenic mouse in models of AIDS cardiomyopathy. AIDS17(Suppl. 1), S36–S45 (2003).
   Google Scholar
• Lu TC, He JC, Klotman P. Animal models of HIV-associated nephropathy. Curr. Opin. Nephrol. Hypertens.15(3), 233–237 (2006).
   PubMed Web of Science ®Google Scholar
• Besnier C, Takeuchi Y, Towers G. Restriction of lentivirus in monkeys. Proc. Natl Acad. Sci. USA99(18), 11920–11925 (2002).
   PubMed Web of Science ®Google Scholar
• Demma LJ, Vanderford TH, Logsdon JM Jr, Feinberg MB, Staprans SI. Evolution of the uniquely adaptable lentiviral envelope in a natural reservoir host. Retrovirology3, 19 (2006).
   Google Scholar
• Hinkula J, Rollman E, Lundholm P, Benthin R, Okuda K, Wahren B. Genetic immunization with multiple HIV-1 genes provides protection against HIV-1/MuLV pseudovirus challenge in vivo. Cells Tissues Organs177(3), 169–184 (2004).
   PubMed Web of Science ®Google Scholar
• Potash MJ, Chao W, Bentsman G et al. A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc. Natl Acad. Sci. USA102(10), 3760–3765 (2005).
   PubMed Web of Science ®Google Scholar
• Bacsi A, Ebbesen P, Szabo J et al. Pseudotypes of vesicular stomatitis virus-bearing envelope antigens of certain HIV-1 strains permissively infect human syncytiotrophoblasts cultured in vitro: implications for in vivo infection of syncytiotrophoblasts by cell-free HIV-1. J. Med. Virol.64(4), 387–397 (2001).
   PubMed Web of Science ®Google Scholar
• Brave A, Ljungberg K, Wahren B, Liu MA. Vaccine delivery methods using viral vectors. Mol Pharm,4(1), 18–32 (2007).
   PubMed Web of Science ®Google Scholar
• Okazaki T, Pendleton CD, Lemonnier F, Berzofsky JA. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen. J. Immunol.171(5), 2548–2555 (2003).
   PubMed Web of Science ®Google Scholar
• Shinoda K, Xin KQ, Okuda K. A modified HIV challenge assay in mice by using luciferase-expressing vaccinia virus. Vaccine24(15), 2751–2754 (2006).
   Google Scholar
• Takahashi H, Cohen J, Hosmalin A et al. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl Acad. Sci. USA85(9), 3105–3109 (1988).
   PubMed Web of Science ®Google Scholar
• Schauber CA, Tuerk MJ, Pacheco CD, Escarpe PA, Veres G. Lentiviral vectors pseudotyped with baculovirus gp64 efficiently transduce mouse cells in vivo and show tropism restriction against hematopoietic cell types in vitro. Gene Ther.11(3), 266–275 (2004).
   PubMed Web of Science ®Google Scholar
• Andang M, Hinkula J, Hotchkiss G et al. Dose-response resistance to HIV-1/MuLV pseudotype virus ex vivo in a hairpin ribozyme transgenic mouse model. Proc. Natl Acad. Sci. USA96(22), 12749–12753 (1999).
   PubMed Web of Science ®Google Scholar
• Lusso P, di Marzo Veronese F, Ensoli B et al. Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science247(4944), 848–852 (1990).
   PubMedGoogle Scholar
• Spector DH, Wade E, Wright DA et al. Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J. Virol.64(5), 2298–2308 (1990).
   Google Scholar
• Hartley JW, Fredrickson TN, Yetter RA, Makino M, Morse HC 3rd. Retrovirus-induced murine acquired immunodeficiency syndrome: natural history of infection and differing susceptibility of inbred mouse strains. J. Virol.63(3), 1223–1231 (1989).
   PubMed Web of Science ®Google Scholar
• Hartley JW, Rowe WP. Naturally occurring murine leukemia viruses in wild mice: characterization of a new “amphotropic” class. J. Virol.19(1), 19–25 (1976).
   PubMed Web of Science ®Google Scholar
• Rasheed S, Gardner MB, Chan E. Amphotropic host range of naturally occuring wild mouse leukemia viruses. J. Virol.19(1), 13–18 (1976).
   PubMedGoogle Scholar
• Miller AD, Chen F. Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry. J. Virol.70(8), 5564–5571 (1996).
   Google Scholar
• Chesebro B, Wehrly K, Maury W. Differential expression in human and mouse cells of human immunodeficiency virus pseudotyped by murine retroviruses. J. Virol.64(9), 4553–4557 (1990).
   Google Scholar
• Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr. Gene Ther.5(4), 387–398 (2005).
   PubMed Web of Science ®Google Scholar
• Spetz AL, Sorensen AS, Walther-Jallow L et al. Induction of HIV-1-specific immunity after vaccination with apoptotic HIV-1/murine leukemia virus-infected cells. J. Immunol.169(10), 5771–5779 (2002).
   PubMed Web of Science ®Google Scholar
• Delebecque F, Combredet C, Gabet AS, Wattel E, Brahic M, Tangy F. A chimeric human T cell leukemia virus type I bearing a δR Moloney-murine leukemia virus envelope infects mice persistently and induces humoral and cellular immune responses. J. Infect. Dis.191(2), 255–263 (2005).
   Google Scholar
• Kavanaugh MP, Miller DG, Zhang W et al. Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc. Natl Acad. Sci. USA91(15), 7071–7075 (1994).
   PubMed Web of Science ®Google Scholar
• Albrecht TR, Lund LH, Garcia-Blanco MA. Canine cyclin T1 rescues equine infectious anemia virus tat trans-activation in human cells. Virology268(1), 7–11 (2000).
   Google Scholar
• Lund LH, Ljungberg K, Wahren B, Hinkula J. Primary murine cells as a model for HIV-1 infection. AIDS18(7), 1067–1069 (2004).
   Google Scholar
• Garber ME, Wei P, KewalRamani VN et al. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev.12(22), 3512–3527 (1998).
   PubMed Web of Science ®Google Scholar
• Sun J, Soos T, Kewalramani VN et al. CD4-specific transgenic expression of human cyclin T1 markedly increases human immunodeficiency virus type 1 (HIV-1) production by CD4+ T lymphocytes and myeloid cells in mice transgenic for a provirus encoding a monocyte-tropic HIV-1 isolate. J. Virol.80(4), 1850–1862 (2006).
   PubMed Web of Science ®Google Scholar
• Bergmeier LA, Lehner T. Innate and adaptive mucosal immunity in protection against HIV infection. Adv. Dent. Res.19(1), 21–28 (2006).
   PubMedGoogle Scholar
• Lehner T. Innate and adaptive mucosal immunity in protection against HIV infection. Vaccine21(Suppl. 2), S68–S76 (2003).
   Google Scholar
• Lehner T, Shearer GM, Hackett CJ, Schultz A, Sharma OK. Alloimmunization as a strategy for vaccine design against HIV/AIDS. AIDS Res Hum Retroviruses,16(4), 309–313 (2000).
   PubMedGoogle Scholar
• Peters B, Whittall T, Babaahmady K, Gray K, Vaughan R, Lehner T. Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection. Lancet,363(9408), 518–524 (2004).
   PubMed Web of Science ®Google Scholar
• Stott EJ. Anti-cell antibody in macaques. Nature353(6343), 393 (1991).
   PubMed Web of Science ®Google Scholar
• Rollman E, Brave A, Boberg A et al. The rationale behind a vaccine based on multiple HIV antigens. Microbes Infect.7(14), 1414 (2005).
   PubMed Web of Science ®Google Scholar
• Rollman E, Mathy N, Brave A et al. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model. Vaccine25(11), 2145–2154 (2007).
   Google Scholar
• Malm M, Rollman E, Ustav M et al. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral Immunol.18(4), 678–688 (2005).
   PubMed Web of Science ®Google Scholar
• Brave A, Hinkula J, Cafaro A et al. Candidate HIV-1 gp140δV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge. Vaccine25(39–40), 6882–6890 (2007).
   Google Scholar
• Zuber AK, Brave A, Engstrom G et al. Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA. Vaccine22(13–14), 1791–1798 (2004).
   PubMed Web of Science ®Google Scholar
• Zuber B. Targeting HIV-1 entry and reverse transcription by vaccination. In: Microbiology and Tumor Biology Center. Karolinska Institute Stockholm, Sweden, 63 (2002).
   Google Scholar
• Johansson S, Goldenberg DM, Griffiths GL, Wahren B, Hinkula J. Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody. AIDS20(15), 1911–1915 (2006).
   PubMedGoogle Scholar
• Ljungberg K, Rollman E, Eriksson L, Hinkula J, Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology302(1), 44–57 (2002).
   PubMedGoogle Scholar
• Rollman E. Concepts in DNA immunization overcoming viral diversity and enhancing plasmid immunogenicity. In: Microbiology and Tumor Biology Center. Karolinska Institute, Stockholm, Sweden (2004).
   Google Scholar
• Brave A, Boberg A, Gudmundsdotter L et al. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8+ T-cell and humoral responses in mice. Mol. Ther.15(9), 1724–1733 (2007).
   PubMedGoogle Scholar
• Gauduin MC, Parren PW, Weir R, Barbas CF, Burton DR, Koup RA. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med.3(12), 1389–1393 (1997).
   PubMed Web of Science ®Google Scholar
• Ruprecht RM, Hofmann-Lehmann R, Smith-Franklin BA et al. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies. Transfus. Clin. Biol.8(4), 350–358 (2001).
   Google Scholar
• Gorantla S, Santos K, Meyer V et al. Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge. J. Virol.79(4), 2124–2132 (2005).
   PubMed Web of Science ®Google Scholar
• Greiner DL, Shultz LD, Yates J et al. Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-SCID/SCID mice. Am. J. Pathol.146(4), 888–902 (1995).
   PubMed Web of Science ®Google Scholar
• Page KA, Landau NR, Littman DR. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J. Virol.64(11), 5270–5276 (1990).
   PubMed Web of Science ®Google Scholar